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Serial changes in glomerular capillary loop gene expression
were used to uncover mechanisms contributing to primary
glomerular disease in rat models of passive Heymann
nephritis and puromycin nephrosis. Before the onset of
proteinuria, podocyte protein-tyrosine phosphatase (GLEPP1)
expression was transiently decreased in the nephrosis model,
whereas the immune costimulatory molecule B7.1 was
stimulated in both models. To relate these changes to the
development of proteinuria, the time of onset and intensity
of proteinuria were altered. When the models were induced
simultaneously, proteinuria and anasarca occurred earlier
with the collapse of glomerular capillary loops. Upregulation
of B7.1 with the downregulation of GLEPP1, Wilms’ tumor
gene (WT1), megalin, and vascular endothelial growth factor
started early and persisted through the course of disease. In
the puromycin and the combined models, changes in GLEPP1
expression were corticosteroid-sensitive, whereas B7.1, WT1,
vascular endothelial growth factor, and most slit diaphragm
genes involved later in the combined model, except podocin,
were corticosteroid-resistant. There was a very early increase
in the nuclear expression of podocyte transcription factors
ZHX2 and ZHX1 that may be linked to the changes in gene
expression in the combined proteinuric model. Our studies
suggest that an early and persistent change in mostly
steroid-resistant glomerular gene expression is the hallmark
of severe and progressive glomerular disease.
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Proteinuria and glomerular disease results from a myriad of
structural and as yet inadequately defined functional changes
in components of the glomerular capillary loop. In different
models, these changes can be variously initiated by
inflammatory cells, complement, cytokines, circulating fac-
tors, or antibody toxicity. Regardless of the initiating event,
changes in one or more of several putative pathways initiate a
sequence of events within the intrinsic components of the
glomerular capillary loop that eventually result in the
development of proteinuria and glomerular disease.
There is a relative paucity of data on gene expression in
experimental primary glomerular disease.1 Most experimental
studies, and all human kidney biopsy studies, have looked at
time points coincident with, or after the onset of proteinuria.
To understand the development of glomerular disease, it is
important to study early changes, especially those just before
the onset of proteinuria. Passive Heymann nephritis (PHN)
and puromycin aminonucleoside nephrosis (PAN) are models
of podocyte disease with a defined time point for the onset of
proteinuria and a pre-proteinuric phase. Both models are
suitable for the study of changes in gene expression before,
and immediately after the onset of proteinuria. In this study,
we induced both models in young rats, because they have very
little baseline proteinuria, and onset of overt proteinuria is
predictably on day 5 (occasionally on day 4).1 Studies in these
models indicate that transient changes in podocyte protein-
tyrosine phosphatase (GLEPP1) and B7.1 occur early, and that
changes in GLEPP1 expression are partially corticosteroid-
sensitive. The potential importance of these gene changes in
the development of proteinuria was assessed by changing the
onset and intensity of proteinuria. Combining the two models
results in the development of glomerular capillary loop
collapse, which is associated with earlier onset of proteinuria,
persistent changes in B7.1 and GLEPP1 expression, increased
early podocyte nuclear expression of ZHX1 and ZHX2,
additional downregulation of several mostly corticosteroid-
resistant genes, and early death from severe anasarca.
RESULTS
Induction of animal models of proteinuria
Proteinuria data of a representative experiment for PAN,
PHN, and PANþ PHN combination is shown in Figure 1. In
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young rats, PAN and PHN cause proteinuria on day 5,
whereas in the PANþ PHN combination, proteinuria devel-
ops on day 2. Lack of proteinuria on day 3 of the individual
models and day 1.5 of the combination model was confirmed
both by protein assay and confocal imaging of proximal
tubules for rat albumin. Because there is a shift to the left in
terms of the onset of proteinuria (i.e., day 2, compared to
days 4–5 in the original models), day 1.5 is taken as a pre-
proteinuric time point, and day 3 as the immediate post-
proteinuric time point.
Histological characterization of the animal models
Histological assessment of each group confirmed the
induction of disease (Figures 2 and 3). PAN and PHN were
histologically similar to previous descriptions extensively
published in the literature. Evidence of significant foot
process effacement was present in the proteinuric PHN, PAN,
and combination rats. This PANþ PHN combination model
has features of both PAN and PHN, for example extensive
foot process effacement as typical of PAN, and subepithelial
deposits as seen in PHN. In the day 6 combination rats,
about a third of the glomeruli had collapsed capillary loops
(see detailed analysis later). Day 1.5 and 3 combination rats
had no evidence of capillary loop collapse. Most PANþ PHN
combination rats develop progressive anasarca early, and die
by days 7–8. The expression of several podocyte markers was
studied in various study groups by immunostaining. Only
results for selected proteins are presented (Figure 4, Figure
S6). As is also noted in human collapsing glomerulopathy,2
Wilms’ tumor gene (WT1), a podocyte-specific transcrip-
tional factor in the adult kidney, was significantly decreased
in glomeruli with collapsed loops, and only mildly decreased
in glomeruli with normal appearing capillary loops in the
combination day 6 rats. WT1 staining was unchanged in PAN
and marginally decreased in PHN at later time points.
Expression of GLEPP1 was moderately decreased even in
glomeruli with noncollapsed loops in the combination day 6
group and severely depleted in those with collapsed loops. In
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Figure 1 | Induction of proteinuria in the PAN, PHN, and PANþPHN combination models. (a) PAN and (b) PHN rats develop proteinuria
on day 5 (occasionally on day 4), whereas (c) PANþ PHN combination rats become proteinuric on day 2. Po0.001 for all proteinuric time
points vs controls in a–c. (d, e) Effect of corticosteroids therapy on proteinuria in (d) PAN and (e) PANþ PHN combination rats is shown.
Rats were treated on alternate days with corticosteroids (see text), resulting in mild decrease in proteinuria. (n¼ 4 rats/group in all
experiments). x indicates Po0.001; xx indicates Po0.01.
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addition, several tubules contained evidence of laminin and
neph1 staining in the luminal protein casts in the day 6
combination group (staining with control IgG-negative),
further supporting shedding of components from the
collapsed glomerular capillary loops. Some proliferating cell
nuclear antigen (PCNA, marker of cell proliferation)-positive
cells are noted to be tethered to the glomerular tuft, whereas
others are noted in the urinary space. Immunostains with
preimmune sera or normal IgG of the same species as the
primary antibody were conducted in each experiment and
were uniformly negative.
Changes in gene expression in PAN, PHN, and PANþPHN
combination
The major reason for inducing the combination model was to
change the onset of proteinuria and study if genes altered
before the onset of proteinuria in the individual models also
moved with the onset of proteinuria. A representative
summary of significant changes in gene expression is listed
in Table 1. Because all the experiments were repeated several
times with multiple measurements for each gene in each
study, the results from a representative study of each kind are
presented.
Slit diaphragm genes
No significant changes in the expression of slit diaphragm
(SD) genes were noted before the onset of proteinuria in
either PAN or PHN, indicating that they cannot be primarily
implicated in the pathogenesis of proteinuria in these
models. Decrease in nephrin and FAT1 expression developed
on days 6 and 10 of PHN, respectively, whereas marginal
decrease in nephrin expression was noted on day 6 in some
PAN studies. SD-related genes are, however, the major new
a b
c d
Figure 2 | Morphological changes in glomeruli in the PANþPHN
combination study on day 6. (a) A control group rat with normal
glomerular morphology on periodic acid-Schiff staining is shown.
(b) A periodic acid-Schiff-stained glomerulus from the study group
with segmental collapse of the capillary loops and some nucleated
cells that are either adherent to the glomerular tuft (arrow) or free in
the urinary space (arrowhead) are shown. (c) A confocal image showing
global collapse of glomerular capillary loops stained with anti-laminin
antibody (red). Nuclei are stained with Sytox green. (d) PCNA
staining (brown) with hematoxylin counterstain in the PANþ PHN
group is shown. The glomerulus has segmental collapse and PCNA-
positive cells adherent to the glomerular tuft (arrow) and free in the
urinary space (arrowhead). The asterisk indicates a dividing podocyte
nucleus, or two very closely placed PCNA-positive cells. Some PCNA-
positive cells are also noted in the parietal capsule and the interstitium.
Control immunostains were negative and are not shown. Original
magnification  400–1000 (for additional images, see Figure S7).
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Figure 3 | Electron microscopy of PAN, PHN, and PANþPHN combination injected rats. Podocyte foot processes were preserved on
day 3 (a) PAN and (b) PHN, and day 1.5 of (c) the PANþ PHN combination. Effacement of foot processes was noted on day 6 (d) PAN
and (e) PHN, and on day 3 (f) PANþ PHN combination. Subepithelial electron-dense deposits (see arrows), a classic feature of PHN,
were also noted in the PANþ PHN combination. Original magnification  10 000–20 000.
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genes that were downregulated in the combination model vs
the individual models.
Podocyte cell surface protein genes
Transient decrease in the GLEPP1 expression (Figure S6)
and increase in B7.1 developed on PAN day 3, both of
which subsided after the onset of proteinuria. In PHN,
increase in B7.1 expression was contributed to both
by the podocyte and infiltrating cells, because CD45
expression was also increased. In the combination model,
the expression of GLEPP1 was persistently decreased,
and that of B7.1 persistently increased through all time
points in the absence of any changes in CD45 expression.
Decrease in megalin expression developed after the onset
of proteinuria in PAN and PHN, and before the onset
of proteinuria in the combination model. A prominent
new feature of the combination model was the decrease in
aminopeptidase A expression late in the combination
group.
Matrix genes
Decrease in COL4A3 and COL4A4 was noted after the onset
of proteinuria in all models. No distinctive features were
noted in this group of genes.
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Figure 4 | Confocal assessment of changes in glomerular protein expression in the PANþPHN study on day 6. (a–c) Low power
images showing absence of albumin staining in the control group, and the presence of albumin (red in B) and neph1 (red in C, arrow) in tubular
casts in the study group. In (d–l), green color identifies nuclei. (d–f) Decrease in b2g1-laminim staining (red) in the (e) noncollapsed and
(f) collapsed glomerular capillary loops is shown. Some laminin is also present in the tubular luminal casts (arrow in f), suggesting breakdown of
the glomerular capillary loop in the study group. (g–l) Severe depletion of WT1 (blue) and GLEPP1 (red) in glomeruli with collapsed loops,
and mild (for WT1) and moderate (for GLEPP1) decrease in glomeruli with preserved capillary loops in the study group, is shown.
Green color identifies all nuclei. Control immunostains using preimmune serum or normal IgG were negative and are not shown. Original
magnification  100–400.
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Table 1 | List of positive fold-changes in rat glomerular gene expression (mean7s.e.) in the various study groups relative to
the corresponding control at the same time point as measured by real-time PCR in PAN, PHN, and PAN+PHN combination
experiments
PAN day 3 PAN day 6 PAN day 10
Podocyte surface proteins Podocyte surface proteins Podocyte surface proteins
kGLEPP1 3.0870.68 kPodocalyxin 3.3971.02 kPodocalyxin 5.7970.48
mB7.1 12.6672.40 kMegalin 5.0970.38 kMegalin 3.7170.45
kb1-Integrin 3.1370.44 Angiogenesis-related
Angiogenesis-related kVEGFA 6.1870.68
kAngiopoietin 1 5.4171.18 kAngiopoietin 2 3.2270.43
GBM/matrix proteins kAngiopoietin 1 6.3072.42
kCOL4A3 3.3770.38 GBM/matrix proteins
kCOL4A4 3.2770.44 kCOL4A3 4.7370.37
kCOL4A4 4.6970.54
PHN day 3 PHN day 6 PHN day 10
Podocyte surface proteins Podocyte surface proteins Podocyte surface proteins
mB7.1 3.4070.52 mB7.1 5.1271.01 mB7.1 5.7671.17
Infiltrating leukocyte marker Angiogenesis-related kGLEPP1 3.6870.51
mCD45 3.8970.42 kVEGFA 4.4170.35 kMegalin 3.8470.43
kAngiopoietin 1 3.1270.60 kPodocalyxin 4.7370.54
SD-related kDystroglycan 6.937 2.35
kNephrin 3.0770.10 kb1-Integrin 3.0570.34
Angiogenesis-related
kVEGFA 5.6670.86
kAngiopoietin 2 3.047 0.68
GBM/matrix proteins
kCOL4A3 4.2770.40
kCOL4A4 2.9770.18
kagrin 3.5370.59
SD-related
kFAT1 3.6070.99
Transcriptional factors
kLMX1B 3.2070.35
kWT1 4.7671.25
Infiltrating leukocyte marker
mCD45 3.270.99
PAN+PHN day 1.5 PAN+PHN day 3 PAN+PHN day 6
Podocyte surface proteins Podocyte surface proteins Podocyte surface proteins
mB7.1 10.7772.45 mB7.1 13.5772.53 mB7.1 3.1470.61
kGLEPP1 7.4070.80 kGLEPP1 9.6571.11 kGLEPP1 30.3773.25
kMegalin 3.8170.22 kMegalin 4.4670.56 kMegalin 7.0770.44
Angiogenesis-related Angiogenesis-related kPodocalyxin 5.5270.24
kVEGFA 3.2470.24 kVEGFA 5.2870.40 kDystroglycan 4.547 1.53
Transcriptional factors kAngiopoietin 1 4.2571.32 kAminopeptidase A 5.0170.35
kWT13.1070.40 SD-related Angiogenesis-related
kPodocin 14.4674.69 kVEGFA 12.6771.15
kAngiopoietin 1 10.1871.05
kAngiopoietin 2 3.2970.41
GBM/matrix proteins
kCOL4A3 9.6770.27
kCOL4A4 6.0970.50
SD-related
kPodocin 14.6873.69
kCD2AP 4.1371.21
kNephrin 7.1970.35
kNephl 5.9970.58
kZO-1 3.0670.56
Transcriptional factors
kWT1 8.1570.15
kpod1 4.7170.83
kLMXIB 4.3270.33
Intracellular proteins
ka-actinin 4 3.6170.62
GBM, glomerular basement membrane; PAN, puromycin aminonucleoside nephrosis; PHN, passive Heymann nephritis; SD, slit diaphragm; VEGFA, vascular endothelial growth
factor A; WT1, Wilms’ tumor gene.
Gene changes before the onset of proteinuria in various models are shaded.
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Intracellular proteins
No major changes in cathepsin expression were noted in any
of the models. Downregulation of a-actinin 4 was a new
change noted only on day 6 of the combination model.
Transcriptional factors
Mild decrease in WT1 and Lmx1b expression were noted on
day 10 of PHN, whereas early and progressively increasing
downregulation of WT1 and late involvement of Lmx1b were
prominent in the combination model. Late decrease in Pod1
expression is a new feature of the combination model.
Angiogenesis-related genes
Whereas changes in the expression of vascular endothelial
growth factor occurred after the onset of proteinuria in PAN
and PHN, early onset of downregulation was a prominent
feature of the combination model.
Effect of corticosteroids on proteinuria and gene expression
patterns
As has been described previously,3 corticosteroids decrease,
but do not abolish, proteinuria in PAN. Proteinuria in the
PAN-steroids and PANþ PHN combination – steroids study
is shown in Figure 1. Light and electron microscopies of
corticosteroid-treated and untreated rats at each time point
were indistinguishable. Statistically significant decrease in
proteinuria was noted in the corticosteroid-treated rats on
day 5 (Po0.001) and day 6 (Po0.01) in the PAN-
corticosteroids (PAN-S) group, and day 6 of the PAN–PHN
combination group (Po0.01), thereby confirming previous
observations that PAN is a partially corticosteroid-responsive
disease model. Proteinuria on day 10 in PAN-S tended to be
less than PAN, but the changes were not statistically
significant. Because changes in expression of genes altered
on day 3 are likely to influence the course of proteinuria as
measured on days 6 and 10, we studied the expression of
GLEPP1 and B7.1 in the corticosteroid-treated and untreated
rats on day 3 (Table 2). Changes in GLEPP1 expression were
corticosteroid-responsive and B7.1 corticosteroid-resistant.
In the combination study, proteinuria was significantly
decreased in the corticosteroid-treated group on day 6
(Figure 1). Treatment with corticosteroids does not otherwise
influence the disease course. Of the genes studied in the
corticosteroid-treated rats on day 1.5 before the onset of
proteinuria, GLEPP1 and megalin were corticosteroid-
sensitive. Most genes that were unique to the combination
model and were altered after the onset of proteinuria were
corticosteroid-resistant, with the notable exception of
podocin (Table 2).
Assessment for glomerular capillary loop collapse was
conducted by an experienced pathologist using sections
stained for laminin and nonspecific nuclear stain Sytox green
(Figures 2 and 4, Figure S7). Significant changes were noted
exclusively in the PANþ PHN combination day 6 and
PANþ PHN combination day 6 steroid-treated groups. Of
253 glomeruli analyzed in the PANþ PHN combination
group day 6, 23% had segmental collapse, 15% had global
collapse, and 62% appeared normal. Of 271 glomeruli
analyzed in the PANþ PHN combination – corticosteroid
group day 6, 20% had segmental collapse, 15% had global
collapse, and 65% appeared normal. Difference between the
two groups was not statistically significant.
Assessment of distribution of ZHX proteins in the PANþPHN
combination model
A recent publication from our laboratory1 shows that the
three members of the ZHX transcriptional factor family,
ZHX1, ZHX2, and ZHX3, are major regulators of podocyte
gene expression in glomerular disease. These proteins are
predominantly sequestered in the nonnuclear compartment
(90–95% for ZHX2 and ZHX3, 80% for ZHX1) in the normal
in vivo podocyte. As shown in that study, the predominant
ZHX protein-related event in puromycin nephrosis is the
transient downregulation, followed by recovery of ZHX3
Table 2 | Effect of corticosteroids treatment on changes in gene expression before the onset of proteinuria (PAN, PAN–PHN
combination), and genes newly altered in the PAN–PHN combination model after the onset of proteinuria
Gene studied PAN day 3 PAN day 3-S P-value Interpretation
GLEPP1 k7.3072.58 k3.7771.32 0.01 Steroid-sensitive
B7.1 m5.9470.34 m7.1171.97 0.43 Steroid-resistant
PAN+PHN day 1.5 PAN+PHN day 1.5-S
GLEPP1 k11.6271.0 k6.3971.35 0.01 Steroid-sensitive
B7.1 m7.7971.79 m8.1671.46 0.87 Steroid-resistant
Megalin k8.3370.62 k4.9670.82 0.006 Steroid-sensitive
VEGF k3.4270.30 k2.6870.32 0.12 Steroid-resistant
WT1 k3.1770.83 k2.3770.66 0.46 Steroid-resistant
PAN+PHN day 6 PAN+PHN day 6-S
Podocin k7.8771.37 k2.6370.25 0.02 Steroid-sensitive
CD2AP k11.1670.84 k30.5773.04 0.003 Steroid-resistant
Neph 1 k5.7570.65 k6.0870.61 0.73 Steroid-resistant
ZO-1 k19.4173.17 k16.9871.92 0.54 Steroid-resistant
a-cactinin 4 k7.0171.0 k7.6070.52 0.62 Steroid-resistant
Aminopeptidase A k14.7071.08 k16.9970.32 0.11 Steroid-resistant
Pod1 k4.7971.07 k7.8670.27 0.02 Steroid-resistant
PAN, puromycin aminonucleoside nephrosis; PHN, passive Heymann nephritis; VEGF, vascular endothelial growth factor A.
Values represent fold – change (mean7s.e.) in expression relative to the corresponding control group at the same time point.
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expression. This is associated with loss of heterodimerization
of ZHX proteins, and entry of ZHX3 into the nucleus
coinciding with the development of proteinuria. Assessment
of staining for ZHX proteins in the combination model
revealed that ZHX1 and ZHX2 were redistributed to the
podocyte nucleus as early as day 1.5, even though decreased
amounts of both proteins were present in the podocyte
(Figure 5). Overall ZHX3 expression was increased, but
redistribution to the nucleus was not prominent. Keeping in
mind that a large number of the genes studied by us are
regulated by ZHX proteins, their increased nuclear presence
suggests that early migration of ZHX2 and ZHX1 are likely to
mediate some of the gene expression changes in the
combination model, for example downregulation of WT1
expression. By contrast, in PHN, changes in the expression of
ZHX proteins were noted after the onset of proteinuria
(Figure S8). By day 10, expression of ZHX1 (nuclear and
nonnuclear) was decreased, and increased podocyte nuclear
expression of ZHX2 and ZHX3 was noted, despite marginal
decrease in expression in the nonnuclear compartment.
DISCUSSION
This paper offers new insight into several aspects of the
pathogenesis of glomerular disease. In PAN and PHN, the
mRNA expression of the podocyte cell–cell proteins (SD
proteins) and the podocyte cell–matrix interaction proteins
(integrins, dystroglycans) did not change before the onset of
proteinuria, indicating that these two important groups of
genes are not directly involved in the pathogenesis of
proteinuria in the models studied. Changes in SD gene
expression are not a prominent feature of PAN, although
marginal changes in nephrin gene expression were noted on
day 6 (after the onset of proteinuria) in one of three PAN
experiments. In PHN, only the expression of nephrin and
FAT1 are significantly decreased after the onset of proteinur-
ia. In the combination model, very early and prominent
involvement of podocin is noted. The SD genes are the major
group of genes that are altered in the combination model and
not in the individual models. Interestingly, some of the genes
altered only in the combination model have been implicated
in the development of focal segmental glomerulosclerosis (a-
actinin 4,4 podocin,5 CD2AP,6 and WT17,8). Other genes that
are new to the combination model include pod1 and
aminopeptidase A.
Whereas the decrease in expression of GLEPP19 after the
onset of proteinuria has been reported previously,10 its
marginal decrease on day 3 of PAN, as observed by us, is even
more meaningful. Downregulation before the onset of
proteinuria migrates to day 1.5 in the combination model,
and is also corticosteroid-sensitive, suggesting a likely role in
the pathogenesis of proteinuria. Even though GLEPP1 /
and þ / mice are not proteinuric,11 this does not contradict
our findings. It is quite likely that that other genes with
similar function may compensate for the lack of GLEPP1 in
a b c
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Figure 5 | Confocal assessment of expression of ZHX proteins in the PANþPHN combination model. Overall expression of podocyte
ZHX1 (green in d, g) and ZHX2 (green in e, h) appears to be decreased in the study group compared to controls (a, b). However, prominent
redistribution of ZHX1 and ZHX2 into the nucleus (arrows in d, e, g, h) is noted as early as day 1.5. Because nuclear ZHX proteins are
transcriptionally active, it is possible that some of the gene expression changes noted in the combination model, including downregulation of
WT1, may be mediated by this early nuclear redistribution of ZHX proteins. The overall expression of ZHX3 appears to be marginally increased
(f, i), but prominent redistribution into the nucleus, as published previously in PAN (c), is not obvious. Blue stain identifies all nuclei. Control
immunostains using preimmune serum or normal IgG were negative and are not shown. Original magnification  400.
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these mice during development. The notable feature of
GLEPP1 in PAN is the transient nature of the change.
Interestingly, we observed persistent downregulation of
GLEPP1 in the combination model. Whether this relates
directly to the rapid downhill course in these rats is not clear.
Changes in B7.1 expression are also revealing. Unlike the
persistent upregulation noted after incubation of cultured
GECs with puromycin aminonucleoside,12 in vivo PAN is
associated with transient upregulation of B7.1 before the
onset of proteinuria. This upregulation occurs in podocytes
and is not related to inflammatory cells, because CD45
expression, a surrogate marker of leukocyte infiltration, is
unchanged. These finding were confirmed by immunostain-
ing day 3 PAN kidney with anti-CD45 antibodies. Upregula-
tion of B7.1 also shifts to day 1.5 in the combination model,
is persistent throughout the time course (in the absence of
CD45 changes, which contrasts it from the PHN pattern),
but, in contrast to GLEPP1, is corticosteroid unresponsive.
None of the genes in our panel were altered on day 1.5 of the
individual models.
In terms of the gene expression profile, with small
exceptions, PAN and PHN alter different genes on day 6.
This is logical, because the known basic mechanisms of injury
are different (e.g. xanthine oxidase stress vs complement-
mediated injury and mitogen-activated protein kinase path-
way activation). When the two models are induced together,
the same early day 3 changes that are noted in the individual
model are also noted on day 1.5 of the combination model,
and because these changes migrate with the onset of
proteinuria, they are also likely to be causally involved in
its development. In the combination model, however, there
are additional changes in gene expression on day 1.5 that
would otherwise occur much later in the individual models.
Moreover, these changes are more severe and persistent in the
combination model. Why does this happen? These models of
podocyte disease are best viewed as a combination of
different pathways, some distinct to each model, and some
shared among these models. The representative genes studied
by us likely belong to at least some of these pathways, but
there are likely to be many other pathways that contain genes
not studied by us. Combining the two models likely
exaggerates the pathways that are common between the two
models, and this may result in the early and persistent
changes in WT1, vascular endothelial growth factor, and
megalin (late day 10 changes in one or both individual
models) noted on day 1.5 of the combination model.
Changes in these pathways, as well as others not studied by
us, are likely to result in the development of a more severe
phenotype in the combination model.
The development of collapse of the glomerular capillary
loops after simultaneous induction of PAN and PHN is an
interesting and novel finding. Whereas there was a major
element of serendipity in this observation, it is interesting
that this approach has never been used previously to vary the
onset of proteinuria, largely because most studies in the past
have focused on the proteinuric phase of glomerular disease,
rather than its pre-proteinuric phase. These observations are
made with unperfused kidneys and with kidneys that were
perfused before killing. Whereas some cells are noted in the
urinary space on day 6 of the combination model, it is not as
prominent as in HIVAN or other forms of human collapsing
glomerulopathy. Therefore, despite the presence of promi-
nent glomerular capillary loop collapse in the day 6
combination rats, we are unable to label this as collapsing
glomerulopathy, which, according to current histological
criteria, required both capillary loop collapse and extensive
epithelial cell proliferation. The lack of extensive epithelial
cell proliferation may be related to the rapid development of
changes in the combination model, and the early death of
these rats from severe anasarca. Alternatively, distinct path-
ways may be involved in the development of capillary loop
collapse, and in epithelial cell proliferation, and that only the
capillary loop collapse-related pathways may be prominently
involved in the combination model. Evidence of shedding of
glomerular basement membrane and podocytes is often
noted in the day 6 PANþ PHN sections as positive staining
for laminin and neph1 in the tubular lumen. In addition,
downregulation of WT1 mRNA and protein expression, a
feature of collapsing glomerulopathy, is noted clearly in the
combination model.
The prominent redistribution of ZHX1 and ZHX2
proteins into the podocyte nucleus in the combination
model, which contrasts with the prominent redistribution of
ZHX3 in PAN recently published by us, is likely to explain
some of the differences in the gene expression profile noted
between the two models, for example presence of WT1
downregulation. Because these changes occur early in the
course of the combination model, they are likely to be at least
partially responsible for the progressive downhill course of
the combination model.
In summary, this paper describes early changes in gene
expression in primary glomerular disease. It also suggests that
simultaneous activation of pathways from two different
disorders can result in the redistribution to the nucleus of
critical transcriptional factors that result in the development
of more severe and rapidly progressive glomerular disease.
Further study will be required to link these changes and
identify additional pathways that may be involved.
MATERIALS AND METHODS
Identification of candidate genes
Candidate genes were selected if they met two or more of the
following criteria: (1) they are critical for maintaining the structure
and function of the glomerular capillary loop; (2) within the
glomerulus, they are relatively specific to the glomerular capillary
loop; and (3) they have been associated with, or have a possibility of
being associated with proteinuria. After classifying these genes into
structural/functional groups, Taqman probes and primer pairs for
each of these genes were developed and tested (Table 3).
Real-time polymerase chain reaction
Real-time polymerase chain reaction (PCR) primers and probes
(FAM-MGB combination) were designed for each gene of interest
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using Primer Express 2.0 software (Applied Biosystems, Foster City,
CA, USA) as described previously.13 All custom designed probes and
control 18S (VIC-MGB) probes were obtained from Applied
Biosystems. Details of real-time PCR and establishment of cutoff
of significance of a threefold change are described in a recent study.1
Each value for change in expression in a study group is relative to
the expression of a control group at the same time point.
Induction of proteinuria
PAN and PHN, both models of podocyte injury, were initially
studied. Glomerular injury was confirmed by measuring proteinur-
ia, and by light microscopy, immunofluorescence microscopy, and
electron microscopy. Glomeruli were extracted using different sets of
autoclaved sieves of similar age. To ensure uniformity of technique,
all key procedures were performed by the same individual
throughout the study. All models were induced at least three times
to ensure the validity of the data. Data from a representative study of
each kind is presented. All animal studies were approved by the
Animal Care and Use Committee at Northwestern University.
Induction of PAN
Puromycin aminonucleoside (15 mg/100 g) or an equivalent volume
of sterile filtered phosphate-buffered saline (PBS) were injected
intravenously once into different groups of 75–100 g male Wistar
rats (n¼ 4 rats/group, baseline proteinuria o1 mg/18 h), and rats
euthanized on days 3, 6, and 10 after injection. Rats develop
Table 3 | Primers and Taqman real-time PCR probes developed for rat glomerular capillary loop genes studied
Gene Forward primer Reverse primer Probe
SD genes
Neph1* TTGCTGCCTTAGTGTTCTTTCTCTAC CCTCAACGTCACATCCTTTCG ACGTCGCAAAGGCAGT
Nephrin* TTCAGCAAGGAGACCTTCAAGAA GCCCCTCAATCCACAGCTT TCACTCACCTTGAATGTGA
ZO-1* GAGCTACGCTTGCCACACTGT TCGGATCTCCAGGAAGACACTT ACCCTAAAACTTGGCAAAA
Podocin TGGAAGCTGAGGCACAAAGA TCCCCTTCGGCAGCAA AGGCCAAAGTGCGGG
CD2AP TCAGTAGACCTTGATGCCTTGGT GGAAGCTATGTCATCAAAATTTACATTATC CAGGAACTCAAAAGAAA
FAT1 TCAGAGTCCTGTGATGACAATGG GAGGAACACTGGGCATCCA ACCACTGGGATACATCAG
P cadherin CCCAAGTTCACTCAAGACACCTT ATCACAGAAGTGCCAGGCATT AGAGGGAGTGTTCCGGAG
Podocyte cell surface protein genes
b1-integrin GGGAATTTGCTAAATTTGAAAAGG TCACGGCACTCTTGTAAATAGGATT AATGCCAAGTGGGACAC
Dystroglycan TTGCCTCCAGTGGAGAAATTATC GACGGCAGGGCCTCCTT AGGTGTCTGCAGCAGG
Podocalyxin CCCTCTACGGCTGCTGTCA GCAGCTCCTCTGTGAGTCGTT TCCCAGAGGAAGGACCCA
Aminopeptidase A GAGGACGGGCAAACCAAGA TCCTGGCATCTGTTGGTTCA ATAGCGGCCACTGAC
GLEPP1 CGAATGTCGATGGTACAGACAGA CATCAGCTGCACGCACTGA AGCAGTACATCTTCATCC
B7.1 GTCACAGAACTTCACCTGGGTAAA CGGAATTGTTTGCTTTTCATCA CCCCAGAAGACCC
Megalin GAAAACCCAAACAGACAACGAACT GCATCCTTTACCTCACTGTCCAT TGAGAACCCAATCTACGCAG
Podocyte intracellular protein genes
a-actinin 4 TCAACTCCAAATGGGAGAAGGT CTGCTTGCTCTGCTCTTCCA CAGCTGGTGCCGAAG
Cathepsin L GGCTATGGTTATGAAGGAACAGATTC CCATTCTTTACCCCAGCTGTTT TAAGGATAAATACTGGCTTGTCA
Cathepsin D GCTAGGAGGCCAAAACTATGAACT TTTCCAGCCTGCGATACCTT CACCCAGAGAAGTACATAC
Cathepsin B GGGTGATAATGGTTTCTTTAAAATCC CCACGATTTCTGATTCAATTCCA CAGAGGAGAGAACCAC
GBM/matrix genes
COL4A3 GGTTTTTCCTTCGTTATGTTTACAAGT GGGCGAGGCAAGTGCTT AGGCTCTGAGGGTGCT
COL4A4 TCTGGATCGGGTACTCATTTCTAAT TGCCCGCCTCCTTGGT CACACTGGAGCTGGG
Entactin GCAATGGAGCCTATAACATATTTGC CCCAGCGTTGCTGCTCTT ATGACAGGGAATCAATGG
Agrin GGCTTCAGTGGTGTCATCCA GCAACACATGCTCCTGAGTCA CTAAGAGGCCATCAACT
Perlecan-probe 1 CGTCAACACCAAGGACATCATC GAGAACTTGCCCCTGGTCAGT TGGTGCCCCAGATGT
Perlecan-probe 2 CGAATATGAGTTCCAGTGCCTTT GGGTTCTCCTCATGCTCACAA TCAAGATGGCTTCAAAG
b2-laminin ACAAGCCAGAGCAGAACAACTG CGCGTTCATTCTCTTCATATGTG TGTTGCAGGCTGCTC
a5-laminin-probe 3 ATTCTCCAGCGCTTTTGCA GGCCAGGCAGCTTCAGACT CTTGGGAGCCCGCC
a5-laminin-probe 4 TGAGGGAGCCGTCACATTAGA CCAGCTCCAGGCTCACATG CAAGGCCAAGATGC
Transcriptional factor genes
Pod1 GCCAACGACAAGTACGAGAATG GCCACCATAAAGGGCCAAGT ATTCACCCAGTCAACC
LMX1B GGGTGACTACGAGAAGGAGAAAGAC CATCTTCATCCTCACTCTTCACAGA CCCGGATGAGTCTGA
WT1 TGGTGCCCAGTACAGAATACACA GATACGCGCCGCACATC CCACGGTGTCTTCCGA
Pax2 AATGTGTCAGGCACACAGACGTA GAGTGGTGCTCGCCATATCA CCCGTCGTGACCGGT
Angiogenesis-related genes
VEGF GCACTGGACCCTGGCTTTAC GTGCAGCCTGGGACCACTT CTGTACCTCCACCATGC
Angiopoietin 1 CAGTACGACAGATTCCACATAGGAA TCCCCGTGTGACCCTTTAAA CCAGAAGCAGAACTACA
Angiopoietin 2-probe 1 GGATGGCTCTGTCAACTTCTTCA CCGTCGATGTTCCCAAACC AACTGGGAGACCTATAAG
Angiopoietin 2-probe 2 CAAGTGTTCCCAGATGCTCACA ACTGTCCATTCAAGTTGGAAGGA TGGTGGTTCGACGCAT
TIE2 receptor GCCAAAATAGCAGATTTTGGATTG AGCCTTCCCATTGTCTTTTTCA CACGAGGTCAAGAAGT
FLT1 AATCAAAACCTTTGAGGAGCTTTC GGTATCCAGATGATAGTCCTCAAACA CCAAATGCCACCTCC
GBM, glomerular basement membrane; SD, slit diaphragm.
*Derived from reference.13
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proteinuria on day 5 (occasionally on day 4). Eighteen-hour urine
collection was obtained in metabolic cages before killing, and
proteinuria was assessed. After killing, heparinized serum was
obtained by cardiac puncture, small sections preserved for histology
as before,13,14 and glomeruli isolated by sieving for total protein13
and total RNA extraction using TRIzol (Invitrogen, Carlsbad, CA,
USA). Total RNA quality and quantity were assessed using OD260,
agarose gel electrophoresis, and the Agilent 2100 bioanalyzer.
Quantification of total RNA extracted from different groups was
done simultaneously, and cDNA templates reverse-transcribed using
2 mg total RNA per template, Superscript III (Invitrogen), and three
identical thermocyclers on the same day. RNase H was added to each
template at the end of reverse transcription. Depending on the
requirements of the experiment, 12–24 cDNA templates were
generated per group. Templates were stored at –201C before
conducting real-time PCR studies.
Induction of PHN
Male Wistar rats (n¼ 4 rats/group, rats weigh 75–100 g) were
injected with 0.4 ml of sheep anti-rat Fx1a or control sheep serum
(Sigma, St Louis, MO, USA) on two consecutive days, and
proteinuria measured on days 3, 6, and 10 after the first injection.
Rats typically become proteinuric on day 4 or day 5. Different
groups of rats were killed on days 3, 6, and 10, kidneys removed, and
processed as for the PAN group.
Induction of PANþPHN combination
We hypothesized that different models of proteinuria may have
some common pathways or mechanisms, and that simultaneous
induction of two models of podocyte injury with similar time of
onset of proteinuria may modify the course of proteinuria. A pilot
study (n¼ 3/ male Wistar rats/group) in which rats were injected
with puromycinþ anti-Fx1a, puromycinþ normal sheep IgG, or
anti-Fx1aþ PBS, and the time of onset of proteinuria noted in all
three groups. The puromycinþ anti-Fx1a group developed
proteinuria at the end of day 2, but not at the end of day 1 or
day 1.5 after the first injection. The combination injected rats died
of anasarca by day 8. The time of onset of proteinuria in the other
two groups was unchanged compared to PAN or PHN, respectively.
A detailed combination study was then conducted. Male Wistar rats
(n¼ 4 rats/group, rats weigh 75–100 g) were injected with anti-Fx1a
as above on two consecutive days (PHN groups), or puromycin
aminonucleoside (PAN groups), a combination of anti-Fx1a on two
consecutive days and puromycin aminonucleoside on day 0
(PANþPHN combination groups), control sheep serum (sheep
serum groups) or PBS (PBS groups), and different groups killed on
days 1.5, 3, 6, and 10. Kidneys from killed rats were processed as
above. To ensure that morphological changes were unrelated to
processing artifacts, the studies were repeated in rats in which
kidneys were perfused via the aorta with PBS before killing.
Corticosteroid treatment study
The overall characteristics of the animals and procedures were
identical to the other experiments discussed above. In the
corticosteroid study, we repeated the PAN (days 1.5, 3, 6, and 10
time points) and the combination study (days 1.5, 3, and 6 time
points), along with two additional studies. In the PAN-S study, rats
were given 3 mg intraperitoneal 6a-methylprednisolone 21-hemi-
succinate on alternate days, starting 24 h after injection of
puromycin aminonucleoside. In view of the shorter lifespan of rats
in the PANþ PHN combination study, the above-mentioned
corticosteroid dose was given intraperitoneally at the same time as
disease induction (PANþPHN combination-S study), and then
continued on alternate days. Corticosteroids did not alter the
longevity of the rats with PANþ PHN combination disease.
Methods for extraction of total RNA and protein, and Western-
blot protocols are described in previous publications.13,14
Imaging studies
Immunofluorescence staining of tissue section was conducted as
described previously.1 Images were acquired in multichannel mode
using a Zeiss Pascal 5 confocal laser microscope using the following
laser and filter combinations: 488 nm argon laser and BP
505–530 nm filter; 543 nm helium-neon laser and BP 560–615 nm
filter; and 633 nm helium-neon laser and LP 650 nm filter.
Antibodies obtained from commercial sources include mouse anti-
human WT1 (sc-7385; Santa Cruz Biotechnology, Santa Cruz, CA,
USA), hamster anti-B7.1 (BD Biosciences, San Jose, CA, USA),
mouse anti-rat CD45 (Cedarlane Laboratories, Hornby, Ontario,
Canada), rabbit anti-rat albumin (Research Diagnostics Inc.
(Flanders, NJ), mouse anti-rat b2g1 laminin (Abcam, Cambridge,
MA, USA), rabbit anti-ZHX1 (Bethyl laboratories, Montgomery,
TX), mouse anti-ZHX2 (Abnova, Taipei city, Taiwan), and anti-
PCNA antibody (Dako Corporation, Glostrup, Denmark). Control
immunostains with preimmune serum or normal IgG of the same
species as the primary antibody were performed for each experi-
ment. Techniques for electron microscopy and light microscopy are
described elsewhere.13–15
Statistical analysis
Analysis of difference in proteinuria or gene expression involving
three or more groups was conducted by ANOVA with post-analysis
testing using GraphPad InStat software (version 3.05). Comparison
of two groups was conducted using the unpaired Student’s t-test in
Microsoft Excel 2000.
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SUPPLEMENTARY MATERIAL
Figure S6. Reduction of GLEPP1 protein (red) expression on day 3 of
puromycin nephrosis prior to the onset of proteinuria.
Figure S7. Additional confocal images showing the development of
segmental (Panels B, C) to global (panels D to F) glomerular collapse
by confocal imaging in day 6 PANþ PHN rats.
Figure S8. Confocal assessment of the expression of ZHX proteins
(red) and WT1 (blue) in glomeruli on PHN day 10.
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